According to reports, GlaxoSmithKline (GSK.US) plans to acquire the biotechnology company IDRx to expand its oncology products.

AASTOCKS · Jan 9 03:35

According to foreign media reports, GlaxoSmithKline (GSK.US) is negotiating to acquire the biotechnology company IDRx, a trade that will further enhance GSK's oncology product portfolio, with IDRx valued at up to 1 billion USD.

IDRx is developing an experimental drug for the treatment of gastrointestinal stromal tumors, which are soft tissue sarcomas occurring in the digestive tract.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

據報葛蘭素史克(GSK.US)擬收購生物技術公司IDRx擴腫瘤產品

According to reports, GlaxoSmithKline (GSK.US) plans to acquire the biotechnology company IDRx to expand its oncology products.

Risk Disclaimer

Statement